CNMD: Organic growth reached 6.7%; FY26 adjusted EPS guidance edged higher
CONMED reported Q3 organic sales growth of 6.7% but a 3.2% YoY decline in adjusted EPS. For FY26, the company narrowed sales guidance and raised adjusted EPS guidance to $4.54–$4.61, according to its 8-K filing.
How this was made
The 30-second read
Why it matters
The EPS guidance raise may attract short‑term buying, while modest sales growth tempers enthusiasm.
Market read
First disclosure of FY26 guidance provides fresh data for traders.
What to watch
Potential supply‑chain constraints or upcoming regulatory reviews could affect future performance.
Background
Conmed Corporation filed an 8‑K on Oct 28, 2026 with Q3 results and FY26 guidance.
Ticker impact
Conmed reported Q3 organic sales up 6.7% YoY and raised FY26 adjusted EPS guidance to $4.54‑$4.61.
slight upside as investors price in higher EPS guidance
Guidance is the first disclosure of FY26 numbers; the EPS range is above prior expectations, while sales growth is modest.
Market effects
Medical device sector may see modest uplift as Conmed signals stable growth.
U.S. healthcare equities could see slight positive bias.
Limited to U.S. listed medical device stocks.
Counterpoint
Guidance may already be priced in; sales growth slowdown could pressure the stock.
Key entities
- companyConmed Corporation
U.S. medical device manufacturer
